MADISON, Wis., May 19, 2021 /PRNewswire/ -- Exact Sciences Corp.
(NASDAQ: EXAS), a global leader in cancer diagnostics, today
announced new data on its cancer tests and treatment guidance tools
will be showcased in seven presentations and one e-abstract at the
2021 American Society of Clinical Oncology (ASCO) Annual Meeting,
being held virtually June 4-8. Data
presented will reinforce the value of the Oncotype DX®
tests in informing personalized treatment decisions and
highlight industry research from Thrive, an Exact Sciences company,
outlining the need to incorporate a blood-based, multi-cancer
screening test into routine clinical care.
Exact Sciences Strengthens Evidence Supporting Cologuard® and
Oncotype DX® Tests w Multiple Data Presentations @ASCO '21
"We're thrilled to participate in ASCO, alongside our
collaborators at leading academic and medical institutions," said
Kevin Conroy, chairman and CEO of
Exact Sciences. "Exact Sciences is changing the way we detect and
treat cancer. The data being presented demonstrate our
commitment to providing earlier answers and life-changing treatment
guidance to patients and physicians, while strengthening our
current tests and accelerating the introduction of new, innovative
diagnostics."
Studies supporting Exact Sciences screening and earlier
detection efforts consist of a Cologuard® (mt-sDNA)
modeling study in collaboration with Mayo Clinic to assess the
impact of sessile serrated polyps on predicted colorectal cancer
outcomes with Cologuard or FIT screening1, and clinical
research from Thrive that emphasizes the need for integrating a
multi-cancer screening test into the standard of
care2.
Data being presented on the Oncotype DX® test
portfolio include a new analysis, based on first results from the
independent RxPONDER study, that reinforce the cost-effectiveness
of the Oncotype DX Breast Recurrence Score® test in
node-positive early-stage breast cancer3; an oral
presentation from the West German Study Group (WSG) on the
prospective phase III ADAPT study which used the Oncotype DX test
to stratify patients with early-stage breast cancer4;
and results from a patient-specific meta-analysis of three
validation studies of the Oncotype DX Colon Recurrence Score
test5.
Also being presented are findings from City of Hope's Center for
Precision Medicine that emphasize a comprehensive sequencing
approach to help guide cancer treatment and assess risk for cancer
and non-cancer diseases, using Exact Sciences' GEM
ExTra® panel6, and early study results from
PFS Genomics Inc., a development stage company founded by radiation
oncologists, recently acquired by Exact Sciences. PFS Genomics has
identified a gene expression signature, named Profile for the
Omission of Local Adjuvant. Radiation (POLAR), to predict whether
women with early-stage invasive breast cancer, treated with breast
conserving surgery, are likely to benefit from
radiotherapy7.
Following are the seven abstracts that have been accepted at the
2021 ASCO Annual Meeting. The on-demand materials, including
posters, will be available in the ASCO Meeting Library, starting at
9:00AM EDT on June 4, 2021.
Impact of the Sessile Serrated Polyp Pathway on Predicted
Colorectal Cancer Outcomes in the CRC-AIM Model
Authors:
Kisiel, J., et al.
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10545
Cancer screening utilization in patients diagnosed with
cancer types with and without recommended screening
modalities
Authors: Cohain, A., et al.
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10557
Utilizing commercial health insurance claims data to identify
the impact of cancer screening and estimate the added benefit of a
multi-cancer liquid biopsy ordered during routine physical
exams
Authors: Cohain, A., Hathaway, C., et al.
Session: Publication Only: Prevention, Risk Reduction, and
Hereditary Cancer
Abstract Number: e22516
Cost-effectiveness of Oncotype DX Breast Recurrence Score
test in postmenopausal women with node-positive early breast cancer
based on the RxPONDER trial
Authors: Berdunov, V., et
al.
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 534
Prognostic impact of Recurrence Score, endocrine response and
clinical-pathological factors in high-risk luminal breast cancer:
Results from the WSG-ADAPT HR+/HER2- chemotherapy
trial
Authors: Gluz, O., et. al
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 504; Oral presentation on June 6, 2021 at 8 AM
EDT.
Discovery and validation of a genomic signature to identify
women with early-stage invasive breast cancer who may safely omit
adjuvant radiotherapy after breast-conserving
surgery
Authors: Sjöström, M., et al.
Session: Breast Cancer – Local/Regional/Adjuvant
Abstract Number: 512
Patient-specific meta-analysis of 3 validation studies of the
12-gene Colon Cancer Recurrence Score Assay for recurrence risk
assessment after surgery with or without 5FU and
oxaliplatin.
Authors: Yothers, G., et al.
Session: Gastrointestinal Cancer – Colorectal and Anal
Abstract Number: 3599
Prospective genomic testing of unselected cancer patients
yields insights about cancer susceptibility and non-cancer disease
with therapeutic implications
Authors: Gray, S., et al
Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract Number: 10603
# # #
About Exact Sciences Corp.
A leading provider of
cancer screening and diagnostic tests, Exact Sciences relentlessly
pursues smarter answers to give people the clarity to take
life-changing action, earlier. Building on the success of
Cologuard® and Oncotype® tests, Exact
Sciences is investing in its product pipeline to support patients
throughout their cancer diagnosis and treatment. Exact Sciences
unites visionary collaborators to help advance the fight against
cancer. For more information, please visit the company's website
at www.exactsciences.com, follow Exact Sciences on Twitter
@ExactSciences, or find Exact Sciences on Facebook.
NOTE: Oncotype,
Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX
Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP
Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are
trademarks or registered trademarks of Genomic Health, Inc. Exact
Sciences and Cologuard are trademarks or registered trademarks of
Exact Sciences Corporation. GEM ExTra is a registered trademark of
Ashion Analytics, LLC, an Exact Sciences Company. All other
trademarks and service marks are the property of their respective
owners.
|
Forward-Looking Statements
This news release contains
forward-looking statements concerning our expectations,
anticipations, intentions, beliefs, or strategies regarding the
future. These forward-looking statements are based on
assumptions that we have made as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially from
those anticipated. You should not place undue reliance on
forward-looking statements. There can be no assurance that we will
be able to (i) realize the anticipated benefit from the acquisition
of PFS Genomics or (ii) successfully develop or commercialize any
products or services utilizing PFS Genomics' technology. Risks and
uncertainties that may affect our forward-looking statements are
described in the Risk Factors sections of our most recent Annual
Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q, and in our other reports filed with the Securities and
Exchange Commission. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
____________________
|
1 Kisiel,
J., et al. Abstract #10545, ASCO 2021.
|
2 Cohain,
A., et al. Abstracts #10557 & e22516, ASCO 2021.
|
3 Berdunov
V. et al. Abstract #534, ASCO 2021.
|
4 Gluz,
O., et. Al. Abstract #504, ASCO 2021.
|
5 Yothers,
G., et al. Abstract #3599, ASCO 2021.
|
6 Gray,
S., et al. Abstract #10603, ASCO 2021.
|
7
Sjöström, M., et al. Abstract #512, ASCO 2021.
|
Investors:
|
Media
(U.S.):
|
Media (Canada,
Europe, Asia, Latin America):
|
Megan
Jones
|
Stephanie
Spanos
|
Federico
Maiardi
|
+1
608-535-8815
|
+1
608-556-4380
|
+41
79-138-1326
|
meganjones@exactsciences.com
|
sspanos@exactsciences.com
|
fmaiardi@exactsciences.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-strengthens-evidence-supporting-cologuard-and-oncotype-dx-tests-and-deep-oncology-pipeline-with-multiple-data-presentations-at-asco-2021-301295421.html
SOURCE EXACT SCIENCES CORP